Asipro vm

Manufactured by Siemens

Sourced in Germany

ASIPro VM is a laboratory equipment product offered by Siemens. It serves as a virtual machine platform for industrial applications. The core function of ASIPro VM is to provide a secure and flexible environment for running industrial software and applications.

Automatically generated - may contain errors

Lab products found in correlation

Inveon pet scanner, by Siemens (4 mentions) Inveon research workplace, by Siemens (1 mentions)

Close spelling variants of this product

ASIPro VM™ Micro PET Analysis software ASIPro

7 protocols using asipro vm

PET/CT Image Analysis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Prism 6.0 was used for plotting graph, fitting curve, and statistical analysis. ASIPro VM (Siemens Medical Solutions, Knoxville, TN) and Amide [21 (link)] was used for PET and PET/CT image analysis.

Lee S.G., Gangangari K., Kalidindi T.M., Punzalan B., Larson S.M, & Pillarsetty N.V. (2016). Copper-64 Labeled Liposomes for Imaging Bone Marrow. Nuclear medicine and biology, 43(12), 781-787.

+ Open protocol

+ Expand

Statistical Analysis of PET Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

Graph Pad Prism 8.0 and Origin 9.0 were used for data statistics and statistical significance calculation. Microsoft Excel 2016 was used for biodistribution and tumor size analysis. PET images were analyzed using ASIPro VM version 6.3.3.0 software (SiemensMedical Solutions). Statistical analysis was performed using the one way/two-way ANOVA or the Student’s t-test with statistical significance assigned at ***P < 0.05 (significant), **P < 0.01 (moderately significant), ***P < 0.001 (highly significant) and ****P < 0.0001 (extremely significant).

Hu K., Xie L., Zhang Y., Hanyu M., Yang Z., Nagatsu K., Suzuki H., Ouyang J., Ji X., Wei J., Xu H., Farokhzad O.C., Liang S.H., Wang L., Tao W, & Zhang M.R. (2020). Marriage of black phosphorus and Cu2+ as effective photothermal agents for PET-guided combination cancer therapy. Nature Communications, 11, 2778.

+ Open protocol

+ Expand

PET Imaging of Experimental Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET scans were conducted using
an Inveon PET scanner (Siemens Medical Solutions, Knoxville, TN, USA),
which provides 159 transaxial slices with 0.796 mm (center-to-center)
spacing, a 10 cm transaxial field of view, and a 12.7 cm axial field
of view. All list-mode acquisition data were sorted into three-dimensional
(3D) sinograms, which were then Fourier-rebinned into two-dimensional
(2D) sinograms (frames × min: 4 × 1, 8 × 2, and 8 ×
5). Experimental mice were kept in the prone position under anesthesia
with 1–2% (v/v) isoflurane during the scan. The tracers (10–17
MBq/100–200 μL) were injected via a preinstalled tail
vein catheter. Immediately after the injection, a dynamic scan in
3D list mode was acquired for 60 min (n = 3). Maximum-intensity
projection (MIP) images were obtained for all mice. PET dynamic images
were reconstructed by filtered back-projection using Hanning’s
filter with a Nyquist cutoff of 0.5 cycle/pixel, which was summed
using analysis software (ASIPro VM, Siemens Medical Solutions, Siemens,
Munich, Germany). Volumes of interest, including the heart, liver,
kidney, and tumor, were placed using the ASIPro software. The radioactivity
was decay-corrected for the injection time and expressed as the percent
of the total injection dose/per gram tissue (% ID/g).

Hu K., Ma X., Xie L., Zhang Y., Hanyu M., Obata H., Zhang L., Nagatsu K., Suzuki H., Shi R., Wang W, & Zhang M.R. (2021). Development of a Stable Peptide-Based PET Tracer for Detecting CD133-Expressing Cancer Cells. ACS Omega, 7(1), 334-341.

+ Open protocol

+ Expand

PET Imaging of Hepatic MAGL Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols

[¹⁸F]MAGL-4-11 synthesis was performed at MGH Cyclotron Facility. PET imaging and quantification were performed as previously described. Briefly, control, CCl₄ and BDL groups were anesthetized with 5% isoflurane gas before 0.1 cc of 3.5–3.7 MBq of [¹⁸F]MAGL-4-11 intravenous injection, and kept thereafter with 1%–2% (v/v) isoflurane. PET/CT was performed for 30 min after intravenous injection of tracer on a Focus 220 preclinical PET system (Siemens) and the CereTom NL 3000 CT scanner (Neurologica). PET/CT image was co-registrated semi-automatically using ASIProVM and Inveon Research Workplace (Siemens Medical Solutions). The magnitude of hepatic [¹⁸F]MAGL-4-11 activation was expressed as %ID/g which was defined as the average [¹⁸F]MAGL-4-11 activity in each volume of interest (VOIs) divided by injected dose.

Shao T., Chen Z., Rong J., Belov V., Chen J., Jeyarajan A., Deng X., Fu H., Yu Q., Rwema S.H., Lin W., Papisov M., Josephson L., Chung R.T, & Liang S.H. (2021). [18F]MAGL-4-11 positron emission tomography molecular imaging of monoacylglycerol lipase changes in preclinical liver fibrosis models. Acta Pharmaceutica Sinica. B, 12(1), 308-315.

+ Open protocol

+ Expand

PET Imaging of Tumor Uptake in Mouse Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET scans were conducted using an Inveon PET scanner (Siemens Medical Solutions, Knoxville, TN, USA), which provides 159 transaxial slices with 0.796 mm (center-to-center) spacing, a 10 cm transaxial field of view, and a 12.7 cm axial field of view. All list-mode acquisition data were sorted into three-dimensional (3D) sinograms, which were then Fourier rebinned into two-dimensional (2D) sinograms (frames × min: 4 × 1, 8 × 2, 8 × 5). Tumor-bearing B16F10/6J Jms or BALB/c nude−/− mice were kept in the prone position under anesthesia with 1–2% (v/v) isoflurane during the scan. The tracers (10–17 MBq/100–200 μL) were injected via a preinstalled tail vein catheter. Immediately after the injection, a dynamic scan in 3D list mode was acquired for 60 min (n = 3). Maximum intensity projection (MIP) images were obtained for C57BL/6J tumor-bearing mice. PET dynamic images were reconstructed by filtered back projection using Hanning's filter with a Nyquist cutoff of 0.5 cycle per pixel, which was summed using analysis software (ASIPro VM, Siemens Medical Solutions). Volumes of interest, including the spleen, muscle and tumor, were placed using the ASIPro software. The radioactivity was decay-corrected for the injection time and expressed as the percent of the total injection dose per gram tissue (% ID g⁻¹).

Hu K., Xie L., Hanyu M., Zhang Y., Li L., Ma X., Nagatsu K., Suzuki H., Wang W, & Zhang M.R. (2020). Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint. RSC Chemical Biology, 1(4), 214-224.

+ Open protocol

+ Expand

PET Imaging of Tumor-Bearing Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET scans were conducted using
an Inveon PET scanner (Siemens Medical Solutions, Knoxville, TN),
which provides 159 transaxial slices with 0.796 mm (center-to-center)
spacing, a 10 cm transaxial field of view, and a 12.7 cm axial field
of view. All list-mode acquisition data were sorted into three-dimensional
(3D) sinograms, which were then Fourier rebinned into two-dimensional
(2D) sinograms (frames × min: 4 × 1, 8 × 2, 8 ×
5). PET dynamic images were reconstructed with filtered back projection
using a Hanning filter and a Nyquist cutoff of 0.5 cycles/pixel. Tumor
bearing mice were kept in the prone position under anesthesia with
1–2% (v/v) isoflurane during the scan. The tracers (8–17
MBq/200–500 μL) in saline were injected via a preinstalled
tail vein catheter. Immediately after the injection, a dynamic scan
in 3D list mode was acquired for 60 min. Maximum intensity projection
images were obtained for tumor bearing mice. PET dynamic images were
reconstructed by filtered back projection using a Hanning filter with
a Nyquist cutoff of 0.5 cycles/pixel, which was summed using analysis
software (ASIPro VM, Siemens Medical Solutions). Volumes of interest,
including the tumors and muscle, were placed using the ASIPro software.
The radioactivity was decay-corrected for the injection time and expressed
as the percent of the total injection dose per gram tissue (%ID/g).

Hu K., Shang J., Xie L., Hanyu M., Zhang Y., Yang Z., Xu H., Wang L, & Zhang M.R. (2020). PET Imaging of VEGFR with a Novel 64Cu-Labeled Peptide. ACS Omega, 5(15), 8508-8514.

+ Open protocol

+ Expand

PET Imaging of Tumor Targeting Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET scans were conducted using an Inveon PET scanner (Siemens Medical Solutions, Knoxville, TN, USA), which provides 159 transaxial slices (Center-to-center spacing: 0.796-mm; transaxial field of view: 10 cm; and axial field of view: 12.7 cm). During the scan, all mice were anesthetized with 1–2% (v/v) isoflurane and kept in a prone position. The BP@⁶⁴Cu@PEG-RGD or BP@⁶⁴Cu@PEG (10–17 MBq per 100 μL) was injected via a preinstalled tail vein catheter. Immediately after injection, a dynamic scan in 3D list mode was acquired at different time points. For each type of tumor, at least three mice were imaged, and MIP images were obtained for all mice. PET static images were reconstructed using an analysis software (ASIPro VM, Siemens Medical Solutions). A filtered back-projection using Hanning’s filter with a Nyquist Cutoff of 0.5 cycle/pixel was used to reconstruct the images. Volumes of interest areas were analyzed using ASIPro software. All radioactivity was decay-corrected based on the injection time and expressed as the percent of the total injection dose/per gram tissue (%ID g⁻¹). For the blocking PET study, excess free c(RGDyC) peptides (5 mg kg⁻¹) were coinjected with BP@⁶⁴Cu@PEG-RGD.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!